SCRIP
CITELINE COMMERCIAL

29 Jun 2020 |

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

Join us for a quick audio roundup of five useful things to know from *Scrip*'s recent coverage of the global biopharmaceutical industry.

This new microcast provides a brief audio tour around *Scrip*'s Five Must-Know Things, in this episode for the week ended 26 June.

On the agenda this time are *Pfizer Inc.* and *Sanofi*'s coronavirus development plans and policies, what increased use of dexamethasone might mean for Indian pharma, *Boehringer Ingelheim International GmbH*'s M&A strategy, and an infographic on the state of global biopharma R&D.

Stories mentioned in this episode:

(Also see "*Pfizer's Bourla On COVID-19 Vaccine: "There Is No ROI That Will Drive Our Decision"*" - Scrip, 22 Jun, 2020.)

(Also see "*Sanofi Confident Of 'Tortoise And Hare' COVID-19 Vaccine Strategy*" - Scrip, 23 Jun, 2020.)

(Also see "*Is Dexamethasone The Next HCQ For Indian Pharma?*" - Scrip, 19 Jun, 2020.)

(Also see "*Boehringer's Philosophy Of Deal-Making: A Conversation With Ioannis Sapountzis And Scott DeWire*" - Scrip, 19 Jun, 2020.)

(Also see "*The 2020 Worldwide Pharma & Biotech Industry R&D Scene*" - Scrip, 24 Jun, 2020.)

Click here to explore this interactive content online

© Citeline 2024. All rights reserved.

SCRIP
CITELINE COMMERCIAL

© Citeline 2024. All rights reserved.